Webinar Date/Time: Tue, Oct 13, 2026 11:00 AM EDT
Negotiated maximum fair prices (MFPs) are now in effect, leaving manufacturers little time to get effectuation right. Join Riparian for practical guidance on MFP compliance, drawn from direct engagement with CMS.
Register Free:
Event Overview:
The first cycle of Medicare-negotiated maximum fair prices (MFPs) is now in effect, and manufacturers face a tight, high-stakes timeline to effectuate them correctly. Making negotiated prices available at the pharmacy counter — across manufacturer, pharmacy and Part D plan workflows — carries real operational and compliance risk, with the next cycle of prices set to take effect soon. This session outlines the essential MFP requirements, current implementation status and deadlines, and practical approaches for meeting program guidelines. Drawing on firsthand engagements with CMS and other stakeholders, it addresses the documentation requirements, operational readiness assessments and compliance verification processes manufacturers need to stay audit-ready.
Key Learning Objectives
Who Should Attend
Speakers
Jennifer Lospinoso
President
Riparian
Jennifer Lospinoso is President of Riparian, an Envision Pharma Group company specializing in pharmaceutical revenue management, government pricing, and market access. With nearly 20 years of leadership—including government rebates, gross-to-net, and contracting for a top-five manufacturer—she has guided manufacturers through regulatory change and recently led MFP effectuation under the IRA across the IPAY 2026 and 2027 cohorts.
Erin Rivas, M.J.
Associate Director
Riparian
Erin Rivas is an Associate Director in Riparian's Consulting practice with over a decade in pharmaceutical and payer commercial operations. Her recent work centers on the maximum fair price under the Medicare Drug Price Negotiation Program—defining requirements, supporting system implementation, and building the policies and procedures for ongoing operations. She has supported all three negotiation cycles and now supports live MFP operations.
Caitlyn Ozier, J.D.
Counsel
King & Spalding
Caitlyn Ozier counsels pharmaceutical, biotech, and medical device companies on regulatory, compliance, and enforcement issues affecting sales, marketing, and pricing. She has extensive experience with key provisions of the Inflation Reduction Act, particularly the Medicare Drug Price Negotiation Program—from initial drug selection through negotiation and maximum fair price effectuation—and advises clients on laws regulating drug pricing.
Register Free:
